Odisha has declared a policy on drugs and medical equipment to bring investments of 25000 crore by 2030. The policy reflects the desire of the state in turning into a large life-sciences hub in eastern India. It was unveiled during the Odisha...
Biocon Biologics Limited, an integrated global biopharmaceutical group and a subsidiary of Biocon Limited have been named under IAM (Intellectual Asset Management). IAM is a leader in international intellectual property publications, to Biocon...
Glenmark Specialty S.A. (GSSA), a wholly owned subsidiary of Glenmark Pharmaceuticals, has signed an exclusive licensing and distribution agreement with Jiangsu Hansoh Pharmaceutical Group. The agreement is for Aumolertinib, a third-generation...
Lupin, a global pharmaceutical company, is making a substantial move towards sustainability. The Science Based Targets initiative (SBTi) certified its greenhouse gas reduction plan, and includes Scope 1, Scope 2, and Scope 3 emissions...
Sanofi said today that tolebrutinib failed to meet its primary endpoint in the PERSEUS phase 3 study in people with primary progressive multiple sclerosis (PPMS), a form of the disease that affects about 10% of the overall MS population...
.jpeg "Akums Strengthens PHN Treatment with Gabapentin ER Launch")
Akums launches an enhanced Gabapentin ER for postherpetic neuralgia, using sustained-release technology to improve pain control, once-daily dosing and patient adherence in India.
AstraZeneca and Daiichi Sankyo received FDA approval for Enhertu as a first?line therapy for HER2-positive metastatic breast cancer, altering treatment for newly diagnosed patients.The ruling will allow the use of Enhertu with Perjeta developed...
Biocon launches its GLP-1 drug Liraglutide in the Netherlands, entering Europe with branded diabetes and obesity therapies, strengthening its GLP-1 and biologics portfolio.
GSK Nucala has moved a step closer to European approval after the EMA’s Committee for Medicinal Products for Human Use (CHMP) recommended the drug for adults with uncontrolled COPD marked by raised blood eosinophils.
Piramal Pharma Solutions NPS has reached a strong 55 for FY2025, signaling high customer loyalty and trust across its global operations. Announced today, the result highlights the company’s growing reputation as a reliable global CDMO and...
.jpg)
, CDSCO.jpg "Fostering a Quality Culture in the Pharmaceutical Industry")